NMS-P937 (NMS1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.
| Pack Size | Availability | Price/USD | Quantity |
|---|---|---|---|
| 2 mg | In stock | $ 82 | |
| 4 mg | In stock | $ 147 | |
| 8 mg | In stock | $ 235 | |
| 20 mg | In stock | $ 414 | |
| 40 mg | In stock | $ 625 |
| Description | NMS-P937 (NMS1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3. |
| Targets&IC50 | PLK1: 2 nM |
| In vitro | Cells are seeded into 96- or 384-well plates at densities ranging from 10,000 to 30,000/cm2 for adherent and 100,000/mL for nonadherent cells in appropriate medium supplemented with 10% fetal calf serum. After 24 hours, cells were treated in duplicate with serial dilutions of NMS-P937, and 72 hours later, the viable cell number was assessed by the CellTiter-Glo Assay (Promega). IC50 values were calculated with a sigmoidal fitting algorithm (Assay Explorer MDL). Experiments were carried out independently at least twice.(Only for Reference) |
| Synonyms | NMS-P937, NMS-1286937 |
| CAS No. | 1034616-18-6 |
| Chemical Formula | C24H27F3N8O3 |
| Molecular Weight | 532.528 |
| Solubility | Ethanol: 10 mg/mL (18.77 mM), warmed DMSO: 39 mg/mL (73.2 mM); H2O: <1 mg/mL |
| Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
In vivo Formulation Calculator (Clear solution)Calculatorbottom
